The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
Cynosure’s technology seems to have been better at destroying value than it was at destroying fat – Hologic has sold the business for a tenth of the purchase price.
The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.
The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Stryker’s scale-building efforts have been notable over the past few years, and at $4.7bn this is its largest-ever deal.
Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.